Evidence map›Paper›PMID 36034698›Full record

ArticleFrontiers in cellular and infection microbiology2022

Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.

Can Cui, Yingying Han, Hongxia Li, Hongxiang Yu, Bei Zhang, Gang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Impact of curcumin on gut microbiome.World journal of experimental medicine · 2025
    Review
  16. Article
  17. Article
  18. The microbiota-gut-brain axis: a potential target in the small-molecule compounds and gene therapeutic strategies for Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Can CuiDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Yingying HanDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Hongxia LiDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Hongxiang YuDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Bei ZhangDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Gang LiDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is a common neurodegenerative disorder, accompanied by motor deficits as well as gastrointestinal dysfunctions. Recent studies have proved that the disturbance of gut microbiota and metabolism contributes to the pathogenesis of PD; however, the mechanisms underlying these effects have yet to be elucidated. Curcumin (CUR) has been reported to provide neuroprotective effects on neurological disorders and modulate the gut flora in intestinal-related diseases. Therefore, it is of significant interest to investigate whether CUR could exert a protective effect on PD and whether the effect of CUR is dependent on the intestinal flora and subsequent changes in metabolites. Methods: In this study, we investigated the neuroprotective effects of CUR on a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 16S rRNA sequencing was performed to explore the profile of the gut microbiota among controls, MPTP-treated mice and CUR-treated mice. Then, antibiotic treatment (ABX) and fecal microbiota transplantation (FMT) experiments were conducted to examine the role of intestinal microbes on the protective effects of CUR in PD mice. Furthermore, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS)-based metabolomics analysis was used to identify the landscape of the CUR-driven serum metabolome. Finally, Pearson's analysis was conducted to investigate correlations between the gut flora-metabolite axis and CUR-driven neuroprotection in PD. Results: Our results showed that CUR intervention effectively improved motor deficits, glial cell activation, and the aggregation of α-synuclein (α-syn) in MPTP-treated mice. 16S rRNA sequencing showed elevated abundances of Conclusions: CUR exerts a protective effect on the progression of PD by modulating the gut microbiota-metabolite axis.

Indexed as

CurcuminGastrointestinal MicrobiomeNeuroprotective AgentsParkinson Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsCreatineDisease Models, AnimalLevodopaMetabolomeMethionineMiceMice, Inbred C57BLNeuroinflammatory DiseasesRNA, Ribosomal, 16SSarcosine1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCreatineCurcuminLevodopaMethionineNeuroprotective AgentsRNA, Ribosomal, 16SSarcosinecurcumindopagut microbiotaParkinson’s diseasetyrosine

Identifiers

PMID36034698
PMCPMC9400544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.